Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma

Response-adapted anti-PD1 based salvage therapy for Hodgkin lymphoma with nivolumab +/- ICE (NICE)

(2022) Matthew G. Mei et al.   BLOOD

Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study

(2021) John Kuruvilla et al.   LANCET ONCOLOGY

Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

(2021) Alison J. Moskowitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma

(2020) Paul J. Bröckelmann et al.   JAMA Oncology

Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

(2020) Richard T. Hoppe et al.   Journal of the National Comprehensive Cancer Network

Pembrolizumab followed by AVD in untreated early unfavorable and advanced stage classical Hodgkin lymphoma

(2020) Pamela Blair Allen et al.   BLOOD

Enhancing anti-tumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors

(2019) K M Heinhuis et al.   ANNALS OF ONCOLOGY

Toxicity patterns associated with chemotherapy/immune checkpoint inhibitor combinations: a meta-analysis

(2019) Omar Abdel-Rahman   Immunotherapy

Five-Year Follow-up of SWOG S0816: Limitations and Values of a PET-Adapted Approach for Stage III/IV Hodgkin Lymphoma

(2019) Deborah M Stephens et al.   BLOOD

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087

(2019) Robert Chen et al.   BLOOD

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial

(2018) Philippe Armand et al.   JOURNAL OF CLINICAL ONCOLOGY

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

(2018) Joseph M. Connors et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis

(2016) Hugo J. A. Adams et al.   ANNALS OF HEMATOLOGY

Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy

(2016) Bruce D. Cheson et al.   BLOOD

Unknown

(2016)   BRITISH JOURNAL OF HAEMATOLOGY

Unknown

(2016)   BRITISH JOURNAL OF HAEMATOLOGY

Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group

(2014) Sally F. Barrington et al.   JOURNAL OF CLINICAL ONCOLOGY

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

(2014) Bruce D. Cheson et al.   JOURNAL OF CLINICAL ONCOLOGY

Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin’s lymphoma: outcome after high-dose chemotherapy and auto-SCT

(2013) S Akhtar et al.   BONE MARROW TRANSPLANTATION

Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496)

(2012) Leo I. Gordon et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Significance of FDG-PET in Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Standard Salvage Chemotherapy and Autologous Stem Cell Transplantation

(2011) Jacob P. Smeltzer et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma

(2011) Heidi Mocikova et al.   LEUKEMIA & LYMPHOMA

Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma

(2010) Andreas Engert et al.   NEW ENGLAND JOURNAL OF MEDICINE